Post-COVID-19 condition: a sex-based analysis of clinical and laboratory trends

Front Med (Lausanne). 2024 Jun 7:11:1376030. doi: 10.3389/fmed.2024.1376030. eCollection 2024.

Abstract

Background and aim: Post-COVID-19 condition (PCC) encompasses long-lasting symptoms in individuals with COVID-19 and is estimated to affect between 31-67% of patients, with women being more commonly affected. No definitive biomarkers have emerged in the acute stage that can help predict the onset of PCC, therefore we aimed at describing sex-disaggregated data of PCC patients from a local cohort and explore potential acute predictors of PCC and neurologic PCC.

Methods: A local cohort of consecutive patients admitted with COVID-19 diagnosis between June 2020 and July 2021 were registered, and clinical and laboratory data were recorded. Only those <65 years, discharged alive and followed up at 6 and 12 months after admission were considered in these analyses. Multivariable logistic regression analysis was performed to explore variables associated with PCC (STATA v 18.0).

Results: From 130 patients in the cohort, 104 were contacted: 30% were women, median age of 42 years. At 6 months, 71 (68%) reported PCC symptoms. Women exhibited a higher prevalence of any PCC symptom (87 vs. 60%, p = 0.007), lower ferritin (p = 0.001) and procalcitonin (p = 0.021) and higher TNF levels (p = 0.042) in the acute phase compared to men. Being women was independently associated to 7.60 (95% CI 1.27-45.18, p = 0.026) higher risk for PCC. Moreover, women had lower return to normal activities 6 and 12 months.

Conclusion: Our findings highlight the lasting impact of COVID-19, particularly in young women, emphasising the need for tailored post-COVID care. The lower ferritin levels in women are an intriguing observation, warranting further research. The study argues for comprehensive strategies that address sex-specific challenges in recovery from COVID-19.

Keywords: COVID-19; long COVID; neurologic long-COVID-19; post COVID-19 condition; sex-disaggregated.

Grants and funding

The authors declare having received financial support for the research, authorship and/or publication of this article. This study was funded by research grants from ANID Fondecyt Regular 1221837 and Pfizer 76883481 receiving PMV. The funding agencies were not involved in the design of the study or in the analysis and interpretation of the data. MCP receives research grants from ANIDCOVID0999 and ANID Fondecyt Regular 1221802.